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During the recent years, the scientific knowledge of the
pathomechanisms and new therapeutic options in
pediatric lung diseases has dramatically increased which
is reflected by the more and more increasing number of
publications in this important field. Additionally, major
scientific efforts have been bundled within national and
international research networks like the German Center
for Lung Research (DZL), the platforms of the European
Respiratory Society (ERS), and the different Cooperation
in Science and Technology (COST) actions [1, 2]. It was
for the first time that the German Society for Pediatric
and Adolescent Medicine (DGKJ) brought together
international lung researchers in an English-speaking
“DGKJ Scientific LUNG Symposium” at the annual
meeting in Munich on September 3 and 4, 2016. The
DGKJ invited frontiers in science covering important
aspects of pediatric lung diseases to discuss their latest
research findings with clinical experts in the field. The
discussion of recent results from animal models and
from molecular studies emphasized the need for an
earlier and better exchange between basic research and
clinical challenges of pediatrics to promote the transla-
tion of experimental results to patient care (and back)
which was also recently promoted, i.e., by the scientific
journal of the European Respiratory Society [3]. All to-
gether, the symposium demonstrated impressively the
relevant similarities and overlaps of pathomechanisms
between the broad spectrum of pediatric lung diseases
which arouse from completely different origins including
inborn, acquired, genetic, and environmental factors.
Pediatric lung disease already starts early in utero
when the highly orchestrated process of lung develop-
ment gets disturbed [4–7]. The balance of signaling
pathways driving alveolar, mesenchymal, and vascular
development including fibroblast growth factor 10 (FGF-
10) signal transduction, the transforming growth factor
beta (TGF-β), hypoxia-inducible factors (HIF), vascular
endothelial growth factor (VEGF-A), and vitamin A-
retinoid signaling represents the prerogative for undis-
turbed alveolo- and vasculogenesis. Surprisingly, not
only the overstimulation of central growth signaling
pathways including the nuclear factor “kappa-light-
chain-enhancer” of activated B cells (NFkB) pathway but
also the reduced baseline activity, i.e., in the absence of a
central regulatory cytokine-like tumor necrosis factor
alpha (TNF-α) can aggravate lung damage [4, 6, 7]. The
complexity of regulation is further enhanced by the
post-transcriptional control of protein production by
microRNAs. Although many studies were able to iden-
tify potential candidates, the proof of causality is still
mostly missing [5]. The central link between pulmonary
inflammation and distortion of lung development is
modulated by amniotic infection and a bundle of well-
established clinical therapies including steroid exposure
as well as the avoidance of mechanical ventilation and
high oxygen exposure [6, 8]. Within the cell populations
contributing to the development of chronic lung disease,
mesenchymal stromal cells have attracted special atten-
tion during the recent years. Animal studies and a first
human study showed a protective effect to the neonatal
lung but a clear separation of the potential mechanisms
of action including growth factor release, immunomodu-
lation, and the substitution of injured cells is necessary
before broad application within clinical trials [9, 10]. We
are just beginning to understand the long-term conse-
quences for these patients [6, 11]. During the presenta-
tions, it became clear that the major pediatric lung
diseases like BPD, asthma, cystic fibrosis, and severe
respiratory viral infections have common and distinct
signaling pathways responsible for disease severity.
Different genetic and epigenetic constellations, the ex-
posure to certain environmental factors, and the hetero-
geneity of immune response determine the clinical
phenotype of asthma, cystic fibrosis, and viral infections
[12–17]. Even within a class of pathogens, the invader
can take different endocytotic pathways and target
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different intracellular sites [16]. Despite the high com-
plexity of immune reactions and pathomechanisms
which might account for differences in phenotype and
treatment responses, there are also promising results
for potential candidates like granulocyte-macrophage
colony-stimulating factor (GM-CSF) to treat different
bacterial and viral infections with the identical
targeted therapy [17].
To this end, the conclusions of the symposium pointed
out that despite the heterogeneities between different
pediatric lung diseases and even between different clin-
ical phenotypes within one disease, the commonalities of
major pathomechanisms highly encourage a comprehen-
sive concept to elucidate the frontiers in science to the
different pediatric lung diseases within a bundled inter-
disciplinary approach. Learning from the others’ cohorts
and experimental results cannot only broaden the hori-
zon but speed up the development and introduction of
new and more specific therapies into the clinics to all
children with pediatric lung diseases. We want to thank
all speakers for their excellent presentations during the
symposium and for their important contributions to this
special edition.
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